In-Vitro Activity of Teicoplanin against Clinical Methicillin Resistant Staphylococcus aureus Isolates

Aim: To evaluate the in vitro activity of teicoplanin against clinical methicillin resistant Staphylococcus aureus isolates was the aim of this study Methods and Material: A total of 62 previously confirmed MRSA isolates were included in this study. Susceptibility testing and result interpretation of isolates to teicoplanin was performed by the E test and disk diffusion method as per Clinical and Laboratory Standards Institute (CLSI) M100-S25 recommendations. Results: Teicoplanin appears to exhibit excellent in vitro activity against the MRSA isolates. Conclusion: The high in vitro susceptibility to teicoplanin in this population and fewer adverse drug effects, teicoplanin may be considered a useful first line antibiotic agent in the treatment of infections caused by MRSA.